The new incubators are set to be operational starting in 2021.
Astellas Pharma, a pharmaceutical products company based in Tokyo, Japan, announced it will invest $13 million into two innovation incubators from LabCentral, a laboratory facility for biotech start-ups in Cambridge, MA, making Astellas one of the five pharmaceutical/biotechnology companies to sponsor the new incubators.
The incubators will consist of lab space for companies to conduct development studies and a non-GMP pilot plant, according to an Oct. 1, 2019 press release. Supporting the incubators will give the company access to healthcare solutions start-ups and entrepreneurial founders looking to expand cell and gene therapy.
Astellas will also invest around $450,000 over a course of three years to become a Gold Sponsor of LabCentral’s Massachusetts-based incubator.
“Accelerating early-stage scientific innovation in areas such as cell and gene therapy is a strategic focus for Astellas, and is superbly aligned with the mission of LabCentral to serve as a launching-pad for cutting-edge biotech and life sciences start-ups,” said Kenji Yasukawa, PhD, president and CEO, Astellas, in the press release
The incubators are set to be operational starting in 2021.
Source: Astellas
Exosomes Field Advances with Milestones Achieved by EXO Biologics and ExoXpert
December 4th 2024EXO Biologics and ExoXpert, an EXO Biologics subsidiary, have received GMP certification of a European manufacturing facility for exosomes and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.